Healthcare provider profile · identity verified

Janet D Pouncy

Nurse Practitioner · RAMER, AL · NPI 1699241042

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	361	119
Amlodipine Besylate	Amlodipine Besylate	318	102
Lisinopril	Lisinopril	153	48
Hydrochlorothiazide	Hydrochlorothiazide	136	44
Losartan Potassium	Losartan Potassium	129	42
Pantoprazole Sodium	Pantoprazole Sodium	124	44
Furosemide	Furosemide	120	37
Omeprazole	Omeprazole	117	40
Metformin Hcl	Metformin Hcl	115	33
Montelukast Sodium	Montelukast Sodium	115	37
Albuterol Sulfate Hfa	Albuterol Sulfate	113	39
Levothyroxine Sodium	Levothyroxine Sodium	109	29
Tamsulosin Hcl	Tamsulosin Hcl	102	33
Jardiance	Empagliflozin	86	21
Duloxetine Hcl	Duloxetine Hcl	85	29
Fluticasone Propionate	Fluticasone Propionate	83	39
Rosuvastatin Calcium	Rosuvastatin Calcium	77	22
Metoprolol Succinate	Metoprolol Succinate	74	19
Trazodone Hcl	Trazodone Hcl	74	30
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	73	21
Simvastatin	Simvastatin	64	22
Carvedilol	Carvedilol	57	19
Hydralazine Hcl	Hydralazine Hcl	56	17
Potassium Chloride	Potassium Chloride	51	16
Ozempic	Semaglutide	50	suppressed
Sertraline Hcl	Sertraline Hcl	50	17
Celecoxib	Celecoxib	49	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	48	22
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	48	15
Tradjenta	Linagliptin	48	11
Trulicity	Dulaglutide	47	suppressed
Famotidine	Famotidine	46	14
Buspirone Hcl	Buspirone Hcl	42	17
Metoprolol Tartrate	Metoprolol Tartrate	40	13
Prednisone	Prednisone	39	34
Breo Ellipta	Fluticasone/Vilanterol	35	suppressed
Glipizide Er	Glipizide	33	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	29
Clonidine Hcl	Clonidine Hcl	31	suppressed
Clopidogrel	Clopidogrel Bisulfate	31	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	31	26
Allopurinol	Allopurinol	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Labetalol Hcl	Labetalol Hcl	28	suppressed
Meloxicam	Meloxicam	28	14
Methocarbamol	Methocarbamol	27	14
Eliquis	Apixaban	26	suppressed
Linzess	Linaclotide	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Glimepiride	Glimepiride	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Glipizide	Glipizide	23	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	21	suppressed
Levetiracetam	Levetiracetam	20	suppressed
Tizanidine Hcl	Tizanidine Hcl	20	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Estradiol	Estradiol	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Atenolol	Atenolol	16	suppressed
Fluconazole	Fluconazole	16	13
Triamcinolone Acetonide	Triamcinolone Acetonide	16	11
Donepezil Hcl	Donepezil Hcl	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Methylprednisolone	Methylprednisolone	14	13
Baclofen	Baclofen	13	suppressed
Cefdinir	Cefdinir	13	12
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Bumetanide	Bumetanide	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error